2025 United Kingdom Artificial Intelligence (Ai) In Drug Discovery Market Revenue Opportunities Report

The 2025 United Kingdom Artificial Intelligence (Ai) In Drug Discovery Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)

The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.

Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)

The report features written analysis and market size statistics on opportunities created in the Artificial Intelligence (AI) in Drug Discovery Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,

The four largest companies actively participating in the UK Artificial Intelligence (AI) in Drug Discovery market are Exscientia, BenevolentAI, Isomorphic Labs (Google DeepMind's spin-off), and Insilico Medicine.

Exscientia, based in Oxford, UK, leads with its AI platform for rapid design and optimization of drug candidates, partnering with major pharma like Sanofi and Bayer. It was the first AI drug discovery company to go public on NASDAQ, boasting a strong pipeline including clinical trial drugs. BenevolentAI, headquartered in London, integrates biological data with machine learning to identify drug targets and optimize molecules. It collaborates with AstraZeneca on multiple disease areas and has a broad pipeline of drug programs.

Isomorphic Labs, a Cambridge-based spin-off of Google DeepMind, utilizes advanced AI models like AlphaFold3 to predict protein structures, accelerating drug discovery. It has high-value collaborations with Eli Lilly and Novartis, expanding small molecule drug discovery research. Insilico Medicine, with a presence in the US and China, also operates globally in the AI-driven drug discovery space using deep learning and generative models to identify novel drug targets, although its UK-specific activities are more limited compared to the first three. These companies represent the core of the UK’s forefront innovation in AI-driven pharmaceutical R&D.

Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.

This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.

Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs. Show more